🔎 Trials Near Me

Gara Jalqabaatti › Leukemia Myeloidii Hamaa › Connecticut

Qorannoo klinikaalii Leukemia Myeloidii Hamaa Connecticut keessatti

Qorannoo 17 Leukemia Myeloidii Hamaa f Connecticut keessatti hirmaatuu jiru.

Magaalota Connecticut keessatti

Takkalaa qorannoo (Ingiliffa)

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Yale University, New Haven
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Yale University, New Haven
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT06317649

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 59 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Connecticut Children's Medical Center, Hartford
  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 3
6 Months – 21 Years · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Connecticut Children's Medical Center, Hartford
  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 1/2
Hanga umuriin 22 · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 3
29 Days – 21 Years · Saalaa hunda · Haaromfame 24-Hag-2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Hartford HealthCare Cancer Institute, Hartford
  • Yale University School of Medicine, New Haven
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Smilow Cancer Hospital at Yale New Haven, New Haven
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 20-Hag-2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • Yale University, Yale Cancer Center, New Haven
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 18-Hag-2026 · NCT06656494

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Yale New Haven Hospital, New Haven
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT01351545

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

  • Yale New Haven Hospital, New Haven
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Wax-2026 · NCT05768932

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Elb-2026 · NCT04256317

Revumenib in Combination With 7+3 + Midostaurin in AML

  • Yale Cancer Center, New Haven
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 25-Bit-2026 · NCT06313437

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Yale Cancer Center and Smilow Cancer Hospital, New Haven
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Bit-2026 · NCT05735184

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • Yale University, New Haven
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Hag-2025 · NCT03850574

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.